Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants

• ClinicalTrials.gov Identifier: NCT04672512
• Recruitment Status: Completed
• First Posted: December 17, 2020
• Last Update Posted: February 9, 2022
• Sponsor: Corcept Therapeutics
• Information provided by (Responsible Party): Corcept Therapeutics

Study Description

Brief Summary:

The purpose of this study is to evaluate the dose-related safety, tolerability, pharmacokinetics (PK) and pharmacological effects (PD) of CORT125329 after single and multiple ascending oral doses of CORT125329 lipid capsule formulations in healthy participants.

Condition or disease	Intervention/treatment	Phase
Healthy	Drug: CORT125329 lipid capsule formulation; Drug: Placebo; Drug: Prednisone	Phase 1

Detailed Description:

This is a 3-part, single-center study of single and multiple ascending doses of CORT125329 in healthy participants.

Part 1 will be a double-blind, randomized, placebo-controlled assessment of single ascending doses (SAD) of CORT125329 lipid capsule formulations. Participants will be enrolled sequentially into 1 of up to 8 cohorts, each containing 8 participants.

Part 2 will be double-blind, randomized, placebo-controlled assessments of multiple oral ascending doses (MAD) of CORT125329 lipid capsule formulations. Participants will be enrolled sequentially into 1 of up to 4 cohorts, each containing 8 participants.

Optional Part 3 will be an open-label, 2-way fixed sequence cross-over study and will serve as proof of PD (glucocorticoid receptor modulation) for CORT125329 lipid capsule formulations. Participants will be enrolled in a single cohort of 10 participants.

Throughout the study, routine safety tests will be performed. In selected parts of the study, assessments of PK (CORT125329), changes in serum cortisol and plasma adrenocorticotrophic hormone (ACTH), and changes in hematological and bone biomarkers will be measured.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 115 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Basic Science
• Official Title: A Phase 1 Adaptive Dose, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered CORT125329 in Healthy Subjects, With an Optional Pharmacological Effects Cohort
• Actual Study Start Date: October 23, 2020
• Actual Primary Completion Date: January 17, 2022
• Actual Study Completion Date: January 17, 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: SAD Cohort A CORT125329; Participants will receive a single dose of CORT125329 30 mg lipid capsule formulation 1 in the fasted state on Day 1	Drug: CORT125329 lipid capsule formulation; CORT125329 lipid capsule formulation 1 or 2 for oral administration
Experimental: SAD Cohort B CORT125329; Participants will receive a single dose of CORT125329 lipid capsule formulation 1 in the fasted state on Day 1. The dose will be determined after review of safety, tolerability, and PK data from SAD Cohort A.	Drug: CORT125329 lipid capsule formulation; CORT125329 lipid capsule formulation 1 or 2 for oral administration
Experimental: SAD Cohorts C through H CORT125329; Participants will receive a single dose of CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Day 1 in a dose escalation format. The dose, formulation, and prandial state for each cohort will be determined after review of safety, tolerability, and PK data from previous cohorts.	Drug: CORT125329 lipid capsule formulation; CORT125329 lipid capsule formulation 1 or 2 for oral administration
Placebo Comparator: SAD Cohorts A through H Placebo; Participants will receive a single dose of placebo matching CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Day 1 in a dose escalation format. The dose, formulation, and prandial state for each placebo cohort will match that used in the corresponding CORT125329 cohort.	Drug: Placebo; Placebo matching CORT125329 lipid capsule formulation 1 or 2 for oral administration
Experimental: MAD Cohorts A through D CORT125329; Participants will receive CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Days 1 through 14 in a dose escalation format. The dose, dose frequency (once- or twice-daily), formulation, and prandial state for each cohort will be determined after review of safety, tolerability, and PK data from previous cohorts.	Drug: CORT125329 lipid capsule formulation; CORT125329 lipid capsule formulation 1 or 2 for oral administration
Placebo Comparator: MAD Cohorts A through D Placebo; Participants will receive placebo matching CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Days 1 through 14 in a dose escalation format. The dose, dose frequency, formulation, and prandial state for each cohort will match that used in the corresponding CORT125329 cohort.	Drug: Placebo; Placebo matching CORT125329 lipid capsule formulation 1 or 2 for oral administration
Experimental: Pharmacodynamic (PD) Effect Cohort; Participants will receive a single dose of prednisone 25 mg in the fasted or fed state on Day 1 of Period 1. The prandial state for the Period 1 treatment will be determined after review of safety and tolerability data from the SAD Cohorts. After a 7-day washout period, participants will receive a single dose of prednisone 25 mg and a single dose of CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Day 1 of Period 2. The formulation and dose level of CORT125329 treatment in Period 2 will be determined after review of safety, tolerability, and PK data from the SAD cohorts. The prandial state for treatment in Period 2 will be the same used in Period 1.	Drug: CORT125329 lipid capsule formulation; CORT125329 lipid capsule formulation 1 or 2 for oral administration; Drug: Prednisone; Prednisone tablet for oral administration

Outcome Measures

Primary Outcome Measures :

1. Percentage of Participants with One or More Adverse Events [ Time Frame: SAD Cohorts: up to Day 11; MAD Cohorts: up to Day 23; PD Effect Cohort: up to Day 2 in Period 1 and up to Day 11 in Period 2 ]
2. Percentage of Participants with One or More Serious Adverse Events [ Time Frame: SAD Cohorts: up to Day 11; MAD Cohorts: up to Day 23; PD Effect Cohort: up to Day 2 in Period 1 and up to Day 11 in Period 2 ]
3. Percentage of Participants Discontinued from the Study Due to an Adverse Event [ Time Frame: SAD Cohorts: up to Day 11; MAD Cohorts: up to Day 23; PD Effect Cohort: up to Day 2 in Period 1 and up to Day 11 in Period 2 ]

Secondary Outcome Measures :

1. Plasma Pharmacokinetics (PK) of CORT125329: Maximum Observed Concentration (Cmax) [ Time Frame: SAD Cohorts: before dosing and at prespecified time points up to Day 11; MAD Cohorts: before dosing and at prespecified time points up to Day 23; PD Effect Cohort: before dosing and at prespecified time points up to Day 11 in Period 2 ]
2. Plasma PK of CORT125329: Elapsed Time from Dosing at which the Analyte was First Quantifiable in a Concentration vs Time Profile (tlag) [ Time Frame: SAD Cohorts: before dosing and at prespecified time points up to Day 11; MAD Cohorts: before dosing and at prespecified time points up to Day 23; PD Effect Cohort: before dosing and at prespecified time points up to Day 11 in Period 2 ]
3. Plasma PK of CORT125329: Time from Dosing at which Cmax was Apparent (Tmax) [ Time Frame: SAD Cohorts: before dosing and at prespecified time points up to Day 11; MAD Cohorts: before dosing and at prespecified time points up to Day 23; PD Effect Cohort: before dosing and at prespecified time points up to Day 11 in Period 2 ]
4. Plasma PK of CORT125329: Apparent Elimination Half-life (t1/2) [ Time Frame: SAD Cohorts: before dosing and at prespecified time points up to Day 11; MAD Cohorts: before dosing and at prespecified time points up to Day 23; PD Effect Cohort: before dosing and at prespecified time points up to Day 11 in Period 2 ]
5. Plasma PK of CORT125329: Area Under the Curve from Zero Time to the Last Measurable Concentration (AUC0-last) [ Time Frame: SAD Cohorts: before dosing and at prespecified time points up to Day 11; PD Effect Cohort: before dosing and at prespecified time points up to Day 11 in Period 2 ]
6. Plasma PK of CORT125329: Area Under the Curve During a Dosing Interval (AUC0-tau) [ Time Frame: MAD Cohorts: before dosing and at prespecified time points up to Day 15 ]
7. Plasma PK of CORT125329: Area Under the Curve from Zero Time Extrapolated to Infinity (AUC0-inf) [ Time Frame: SAD Cohorts: before dosing and at prespecified time points up to Day 11; PD Effect Cohort: before dosing and at prespecified time points up to Day 11 in Period 2 ]
8. Serum Cortisol [ Time Frame: MAD Cohorts: before dosing in the morning of Days 1 and 14 and in the evening of Days -1 and 14 ]
9. Plasma Adrenocorticotrophic Hormone (ACTH) [ Time Frame: MAD Cohorts: two samples taken before dosing in the morning of Days 1 and 14 and in the evening of Days -1 and 14 ]
10. Eosinophil Count [ Time Frame: PD Effect Cohort: before dosing and at prespecified time points up to 24 hours after dosing in Period 1 and 2 ]
11. Lymphocyte Count [ Time Frame: PD Effect Cohort: before dosing and at prespecified time points up to 24 hours after dosing in Period 1 and 2 ]
12. Neutrophil Count [ Time Frame: PD Effect Cohort: before dosing and at prespecified time points up to 24 hours after dosing in Period 1 and 2 ]
13. Serum Osteocalcin [ Time Frame: PD Effect Cohort: before dosing and at prespecified time points up to 24 hours after dosing in Period 1 and 2 ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 60 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Body mass index of 18.0 to 30.0 kg/m^2
• Weight of ≤102 kg
• Must agree to adhere to the contraception requirements
• Additional criteria apply.

Exclusion Criteria:

• Received any investigational medicinal product in a clinical research study within the 90 days
• History of any drug or alcohol abuse in the past 2 years
• Regular alcohol consumption
• Current smokers and those who have smoked within the last 6 months
• Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 6 months
• Females of childbearing potential including those who are pregnant or lactating (all female subjects must have a negative pregnancy test at screening and admission)
• Clinically significant abnormal clinical chemistry, haematology or urinalysis as judged by the Investigator
• Confirmed positive drugs of abuse test result
• Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results
• Active renal and/or hepatic disease
• History of clinically significant cardiovascular, renal, hepatic, endocrine, metabolic, respiratory, GI, neurological or psychiatric disorder, as judged by the Investigator
• Any form of cancer within the last 5 years (exceptions apply)
• History and/or symptoms of adrenal insufficiency
• History of clinically significant gastrointestinal disease
• Has a condition that could be aggravated by glucocorticoid antagonism
• Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
• Presence or history of clinically significant allergy requiring treatment
• Donation or loss of greater than 400 mL of blood or plasma within the previous 3 months
• Are taking, or have taken, any prescribed, over-the-counter drug (other than 4 g per day paracetamol), vitamins or herbal remedies within 14 days before the study (exceptions may apply on a case by case basis)
• Are currently using glucocorticoids or have a history of systemic glucocorticoid use at any dose within the last 12 months or 3 months for inhaled products
• Additional criteria apply.

Contacts and Locations

Locations

United Kingdom

Quotient Sciences

Ruddington, Nottingham, United Kingdom, NG11 6JS

Sponsors and Collaborators

Corcept Therapeutics

Investigators

• Principal Investigator: Sharan Sidhu, MBChB, BAO, MRCS, MFPM; Quotient Sciences

More Information

• Responsible Party: Corcept Therapeutics
• ClinicalTrials.gov Identifier: NCT04672512
• Other Study ID Numbers: CORT125329-140; 2020-001741-38 ( EudraCT Number )
• First Posted: December 17, 2020
• Last Update Posted: February 9, 2022
• Last Verified: February 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Prednisone; Anti-Inflammatory Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Physiological Effects of Drugs; Antineoplastic Agents, Hormonal; Antineoplastic Agents